Skip to content

Comparison of Dexmedetomidine and esketamine in Preventing Cardiovascular Response to Sufentanil-Etomidate-induced Double-lumen Endotracheal Intubation under Cardiac Ultrasound

Comparison of Dexmedetomidine and esketamine in Preventing Cardiovascular Response to Sufentanil-Etomidate-induced Double-lumen Endotracheal Intubation under Cardiac Ultrasound

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028030
Enrollment
Unknown
Registered
2019-12-08
Start date
2019-12-09
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular reaction

Interventions

Group A:Before induction,pump at 0.8 µg / kg dexmedetomidine + 20 mL NS(injection completed within 10 minutes).
Group B:Before induction,pump at 0.75 mg / kg esketamine + 20 mL NS(injection completed within 10 minutes).
Group C: 20 mL NS(injection completed within 10 minutes).

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II grade; 2. Aged 18-75 years; 3. Patients undergoing double-lumen tracheal intubation; 4. Preoperative examination without tracheal intubation.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrolled hypertension, severe arrhythmia, history of coronary heart disease, cerebral hemorrhage, cerebral infarction, or other cardiovascular and cerebrovascular diseases; 2) Patients with liver and kidney insufficiency, patients with chronic obstructive pulmonary disease; 3) The patient suffers from mental diseases; 4) Allergy to test drugs and other anesthetic-induced drugs; 5) Participants in other clinical trials in the study; 6) Patients who are expected to have difficulty intubation or need multiple attempts at intubation; 7) Women who are pregnant; 8) Those who have taken cardiovascular drugs before entering the house.

Design outcomes

Primary

MeasureTime frame
Changes in heart rate and baseline heart rate at each time point, incidence and duration of stress response (maximum heart rate - baseline heart rate);

Secondary

MeasureTime frame
Left ventricular function;perioperative low blood pressure, high blood pressure, cardiac arrhythmia events (see annex), postoperative hospital stay, and other adverse events within 30 days after surgery;each period of blood pressure and ST segment changes;

Countries

China

Contacts

Public ContactLin Wenqian

Sun Yat-Sen University Cancer Center

linwq@sysucc.org.cn+86 13825149286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026